The paradigm for the treatment of multiple myeloma (MM) has significantly
changed: therapeutic options have evolved from the introduction of melphalan and prednisone
in the 1960s, high-dose chemotherapy and stem cell transplantation in the late 1980s and 1990s,
to the rapid introduction of small novel molecules within the last seven years. Based on the
understanding of the complex interaction of MM cells with bone marrow microenvironment;
and of the role of neoangiogenesis in MM pathogensis, a number of novel therapeutic agents
with anti-angiogenic properties are now available, playing a key role in the treatment of MM
both in the preclinical settings and as part of clinical trials.
